MRK: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/fea24815-2c93-4898-ace1-8974d5c9f1a6/","filing_uuid":"fea24815-2c93-4898-ace1-8974d5c9f1a6","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/fea24815-2c93-4898-ace1-8974d5c9f1a6/print/","filing_document_content_type":"text/html","income":"40000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mathew Lapinski","dt_posted":"2026-07-17T11:08:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 North Capitol Street, NW, Suite 800","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":400531586,"url":"https://lda.gov/api/v1/registrants/400531586/","house_registrant_id":null,"name":"CROSSROADS STRATEGIES, LLC","description":"lobbying firm","address_1":"800 North Capitol Street, NW, Suite 800","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MATHEW LAPINSKI","contact_telephone":"+1 202-559-0170","dt_updated":"2026-07-30T15:56:39.212913-04:00"},"client":{"id":192168,"url":"https://lda.gov/api/v1/clients/192168/","client_id":431,"name":"MERCK & CO., INC.","general_description":"developer, manufacturer and distributor of pharmaceuticals","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-01-01"},"lobbying_activities":[{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}